
## CLAIMS

1. A combination for simultaneous, separate or sequential administration comprising at least one sigma ligand of formula (I), or a pharmaceutically acceptable salt, isomer, prodrug selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphates, or solvate thereof, and at least one opioid or opiate selected from the group consisting of morphine or a structurally derivative thereof, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine, for use in the prevention and/or treatment of pain developed as a consequence of surgery



(I)

wherein,

$R_1$ is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, or halogen;

$R_2$ is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, or halogen;

$R_3$ and $R_4$ are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, or halogen, or together they form an optionally substituted fused ring system;

$R_5$ and $R_6$ are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted heterocyclylalkyl, $-COR_8$, $-C(O)OR_8$, $-C(O)NR_8R_9$, $-CH=NR_8$, $-CN$, $-OR_8$, $-OC(O)R_8$, $-S(O)_t-R_8$, $-NR_8R_9$, $-NR_8C(O)R_9$, $-NO_2$, $-N=CR_8R_9$, or halogen;

or together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

**n** is selected from 1, 2, 3, 4, 5, 6, 7 or 8;

**t** is 1,2 or 3;

$R_8$ and $R_9$ are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, or halogen,

wherein the substituted groups are substituted at one or more available positions by one or more groups selected from the group consisting of halogen; cyano; hydroxyl; nitro; azido; alkanoyl; carboxamido; alkyl groups; alkenyl and alkynyl groups; alkoxy groups; aryloxy; alkylthio groups; alkylsulfinyl groups; alkylsulfonyl; aminoalkyl groups; carbocylic aryl and aralkyl.

2. A combination according to claim 1 wherein $R_1$ is selected from H, $-COR_8$, or substituted or unsubstituted alkyl.

3. A combination according to claim 1 or 2 wherein $R_2$ is H or alkyl.

4. A combination according to any of the preceding claims wherein $R_3$ and $R_4$ are situated in the meta and para positions of the phenyl group.

[53] 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole,

[55] 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine,

[56] N-benzyl-4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-methylbutan-1-amine,

[57]4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1-amine,

[58] 4-{4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]butyl}thiomorpholine,

[59]1-[1-(3,4-Dichlorophenyl)-5-methyl-3-(2-morpholinoethoxy)-1H-pyrazol-4-yl]ethanone,

[60]1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazol-4-yl}ethanone,

[61] 1-{1-(3,4-dichlorophenyl)-5-methyl-3-[2-(piperidin-1-yl)ethoxy]-1H-pyrazol-4-yl}ethanone,

[62] 1-{1-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethoxy]-5-methyl-1H-pyrazol-4-yl}ethanone,

[63] 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine,

[64] N,N-Diethyl-2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy] ethanamine,

[65] 1-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}piperidine,

[66] 5-Methyl-1-(naphthalen-2-yl)-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole

or its pharmaceutically acceptable salts, solvates or a prodrug thereof, wherein the prodrug is selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphates.

~~10. A combination according to any of the preceding claims comprising an opioid or opiate selected from the group consisting of morphine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine or an analogue thereof.~~

~~11~~10. A combination according to any of the preceding claims wherein the combination comprises 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

~~12~~11. A combination according to claim 1 wherein the combination comprises 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and an opioid or opiate selected from the group consisting of morphine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine.

~~13~~12. A sigma ligand of formula (I) as defined in any of claims 1-9, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, wherein the prodrug is selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphates, for use in potentiating the analgesic effect of an opioid or opiate as defined in claim 1 and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

~~14~~13. A sigma ligand of formula (I) as defined in any of claims 1-9, or a pharmaceutically acceptable salt, isomer, prodrug selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphates, or solvate thereof, for use in potentiating the analgesic effect of an opioid or opiate as defined in claim 1 when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

~~15~~14. A sigma ligand of formula (I) as defined in any of claims 1-9, or a pharmaceutically acceptable salt, isomer, prodrug selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphates, or solvate thereof, for use in decreasing the dependency induced by an opioid or opiate as defined in claim 1 when said opioid or opiate is used to the prevention and/or treatment of pain developed as a consequence of surgery.